alexa The Newest Targeted Therapeutics for Thyroid Cancer: Development of Sorafenib and Lenvatinib | OMICS International | Abstract
ISSN: 2167-7700

Chemotherapy: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Commentary

The Newest Targeted Therapeutics for Thyroid Cancer: Development of Sorafenib and Lenvatinib

Mark Steven Cohen*

Department of Surgery, Section of General Surgery, Division of Endocrine Surgery University of Michigan Comprehensive Cancer Center, 2920K Taubman Center,1500 East Medical Center Drive, SPC 5331 Ann Arbor, Michigan, USA

*Corresponding Author:
Mark Steven Cohen
Department of Surgery
Section of General Surgery
Division of Endocrine Surgery University of Michigan Comprehensive Cancer Center
2920K Taubman Center,1500 East Medical Center Drive
SPC 5331 Ann Arbor, Michigan, USA
Tel: 734 - 615-4741
E-mail: [email protected]

Received date: 14 August, 2015; Accepted date: 30 September, 2015; Published date: 05 September, 2015

Citation: Cohen MS (2015) The Newest Targeted Therapeutics for Thyroid Cancer: Development of Sorafenib and Lenvatinib. Chemo Open Access 4:168. doi:10.4172/2167-7700.1000168

Copyright: © 2015 Cohen MS. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Sorafenib was specifically developed using high-throughput screening and structure-activity relationships to target important pathogenic pathways in thyroid cancer. Initially developed to target rapidly accelerated fibrosarcoma (RAF) kinase, it was also found to inhibit several key receptor tyrosine kinases (RTKs) within the mitogen-activated protein kinase (MAPK) pathway. Preclinical and clinical studies demonstrated significant efficacy in differentiated thyroid cancer (DTC), and following the phase III DECISION trial comparing sorafenib to placebo in DTC, it received Food and Drug Administration (FDA) approval in November 2013 for treatment of advanced, radioactive iodine-refractory DTC. Sorafenib is shown to significantly improve progression free survival (PFS) an average of 10.8 months (hazard ratio [HR] 0.59, 95% CI, 0.45-0.76; P<0.0001), although an overall survival (OS) benefit has yet to be proven. An additional targeted RTK inhibitor, lenvatinib, was recently approved by the FDA in February 2015 for advanced, RAIrefractory DTC following the phase III SELECT trial. While lenvatinib has a higher average PFS of 18.3 months (HR 0.21; 99% CI, 0.14-0.31; P<0.001), as well as higher complete and partial response rates, it too has yet to prove an OS benefit. While there is clear evidence of the clinical benefit for both sorafenib and lenvatinib treatment in advanced RAI refractory patients, it is unclear which may be superior. However, each has a different side effect profile that may help guide initial treatment decisions in an individualized approach. Additionally, because lenvatinib demonstrated a similar increase in PFS for those who were previously treated with RTK inhibitors like sorafenib, lenvatinib is a powerful addition to the treatment of advanced DTC and creates another option for either initial therapy or secondary therapy following disease progression.

Keywords

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version